Bio-Gene Technology (ASX:BGT) Common Stock: A$23.89 Mil (As of Dec. 2025)


What is Bio-Gene Technology Common Stock?

Bio-Gene Technology ASX:BGT Common Stock is A$23.89 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's quarterly common stock increased from Dec. 2024 (A$21.53 Mil) to Jun. 2025 (A$22.95 Mil) and increased from Jun. 2025 (A$22.95 Mil) to Dec. 2025 (A$23.89 Mil).

Bio-Gene Technology's annual common stock increased from Jun. 2023 (A$19.55 Mil) to Jun. 2024 (A$21.53 Mil) and increased from Jun. 2024 (A$21.53 Mil) to Jun. 2025 (A$22.95 Mil).

Bio-Gene Technology Common Stock Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Common Stock Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial 15.06 19.55 19.55 21.53 22.95

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.53 21.53 21.53 22.95 23.89

Bio-Gene Technology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$23.89 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Common Stock of A$23.89 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Common Stock too high?
Bio-Gene Technology's current Common Stock is A$23.89 Mil.
How does Bio-Gene Technology's Common Stock compare to VRTX and REGN?
Bio-Gene Technology's Common Stock of A$23.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Common Stock is A$23.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Common Stock of A$23.89 Mil. The current Common Stock is A$23.89 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Common Stock is A$23.89 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.